Pathways in small cell lung cancer and its therapeutic perspectives
© 2021 The Author(s). Published by BRI..
Small cell lung cancer (SCLC) is known for its rapid growth with high metastatic spread. Its treatment remains a major challenge for oncologists due to the high mutation rate and other clinical disadvantages. The survival rate of these patients is very poor but there is no significant progress over the last few decades in the treatment protocols. Hence there is an urgency to design new clinical trials with novel drug combinations that can specifically and effectively target key pathways for proper treatment of SCLC. There have been several indications that developmental signalling pathways are involved in tumor growth, progression, metastasis and invasion of SCLC. Thus, it is anticipated that deciphering the signalling cascades of these embryonic signalling pathways may reveal novel therapeutic breakthroughs in SCLC. In this context, we have tried to assemble all the relevant information to give an updated overview of the various signalling pathways involved in the development of SCLC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Frontiers in bioscience (Landmark edition) - 26(2021), 12 vom: 30. Dez., Seite 1668-1678 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shivapriya, Pingali M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
FGF pathway |
|---|
| Anmerkungen: |
Date Completed 13.01.2022 Date Revised 13.01.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.52586/5059 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335295126 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335295126 | ||
| 003 | DE-627 | ||
| 005 | 20231225225513.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.52586/5059 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1117.xml |
| 035 | |a (DE-627)NLM335295126 | ||
| 035 | |a (NLM)34994180 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shivapriya, Pingali M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pathways in small cell lung cancer and its therapeutic perspectives |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.01.2022 | ||
| 500 | |a Date Revised 13.01.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 The Author(s). Published by BRI. | ||
| 520 | |a Small cell lung cancer (SCLC) is known for its rapid growth with high metastatic spread. Its treatment remains a major challenge for oncologists due to the high mutation rate and other clinical disadvantages. The survival rate of these patients is very poor but there is no significant progress over the last few decades in the treatment protocols. Hence there is an urgency to design new clinical trials with novel drug combinations that can specifically and effectively target key pathways for proper treatment of SCLC. There have been several indications that developmental signalling pathways are involved in tumor growth, progression, metastasis and invasion of SCLC. Thus, it is anticipated that deciphering the signalling cascades of these embryonic signalling pathways may reveal novel therapeutic breakthroughs in SCLC. In this context, we have tried to assemble all the relevant information to give an updated overview of the various signalling pathways involved in the development of SCLC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a FGF pathway | |
| 650 | 4 | |a Hedgehog pathway | |
| 650 | 4 | |a Notch pathway | |
| 650 | 4 | |a Signalling pathways | |
| 650 | 4 | |a Small cell lung cancer | |
| 650 | 4 | |a Therapeutics | |
| 700 | 1 | |a Singh, Anirudh |e verfasserin |4 aut | |
| 700 | 1 | |a Pandey, Priyanshu |e verfasserin |4 aut | |
| 700 | 1 | |a Chhabra, Nandini |e verfasserin |4 aut | |
| 700 | 1 | |a Sahoo, Amaresh Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Paital, Biswaranjan |e verfasserin |4 aut | |
| 700 | 1 | |a Varadwaj, Pritish Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Samanta, Sintu Kumar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in bioscience (Landmark edition) |d 2009 |g 26(2021), 12 vom: 30. Dez., Seite 1668-1678 |w (DE-627)NLM186959230 |x 2768-6698 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2021 |g number:12 |g day:30 |g month:12 |g pages:1668-1678 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.52586/5059 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2021 |e 12 |b 30 |c 12 |h 1668-1678 | ||